Program
Clarithromycin
Also written as “clarithromycin”, “Clarithromycin ER 500 mg tablets” and “Clarithromycin 500mg”.
Its studies are mostly in Mycobacterium avium-intracellulare Infection · Infections · HIV Infections · Bronchiectasis · Crohn Disease, led by 19 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Abbott | 50 open or running | phase 3since Mar 22, 2008 | Nov 2, 1999 | none ahead |
| Sun Pharmaceutical Industries | 50 open or running | phase 1since Oct 15, 2008 | Oct 15, 2008 | none ahead |
| Teva Pharmaceutical Industries | 40 open or running | phase 1since Feb 2, 2009 | Feb 2, 2009 | none ahead |
| Pfizer | 30 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Viatris | 30 open or running | phase 1since Mar 31, 2008 | Mar 31, 2008 | none ahead |
| Boehringer Ingelheim | 20 open or running | phase 1since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince Sep 20, 2007 | Sep 20, 2007 | none ahead |
| HK inno.N | 20 open or running | phase 1since Jan 7, 2014 | Jan 7, 2014 | none ahead |
| Johnson & Johnson | 20 open or running | phase 1since Jan 15, 2015 | Jan 15, 2015 | none ahead |
| Novartis | 20 open or running | phase 1since Apr 13, 2009 | Apr 13, 2009 | none ahead |
| antios-therapeutics-inc | 10 open or running | phase 1since Oct 28, 2021 | Oct 28, 2021 | none ahead |
| Italfarmaco | 10 open or running | phase 1since Apr 26, 2023 | Apr 26, 2023 | none ahead |
| Jiangsu HengRui Medicine | 11 open or running | phase 1since Jul 6, 2026 | Jul 6, 2026 | none ahead |
| phathom-pharmaceuticals-inc | 10 open or running | phase 3since Nov 15, 2019 | Nov 15, 2019 | none ahead |
| PTC Therapeutics | 10 open or running | phase 1since Nov 4, 2014 | Nov 4, 2014 | none ahead |
| redhill-biopharma-limited | 10 open or running | phase 3since Dec 26, 2016 | Dec 26, 2016 | none ahead |
| shandong-luoxin-pharmaceutical-group-stock-co-ltd | 10 open or running | phase 1since Jun 2, 2023 | Jun 2, 2023 | none ahead |
| Sihuan Pharmaceutical Holdings Group | 10 open or running | phase 1since May 15, 2020 | May 15, 2020 | none ahead |
| Yuhan | 10 open or running | phase 1since Aug 8, 2013 | Aug 8, 2013 | none ahead |
Also a collaborator on its studies: genpharm-ulc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Nov 2, 1999.
- Aug 8, 2013Yuhan's first study: phase 1 study in HealthyNew to YuhanYuhan · NCT01921647 · 95 enrolled · Korea, Republic of
- Jan 7, 2014HK inno.N's first study: phase 1 study in HealthyNew to HK inno.NHK inno.N · NCT02052336 · 24 enrolled · Korea, Republic of
- Sep 25, 2014Phase 1 study in HealthyBoehringer Ingelheim · NCT02251769 · 24 enrolled
- Nov 4, 2014PTC Therapeutics's first study: phase 1 study in Healthy VolunteersNew to PTC TherapeuticsPTC Therapeutics · NCT02286635 · 58 enrolled · United States
- Jan 15, 2015Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT02343289 · 18 enrolled · Belgium
- Dec 13, 2016Phase 1 study in Drug InteractionHK inno.N · NCT03011996 · 60 enrolled · Korea, Republic of
- Dec 26, 2016redhill-biopharma-limited's first study: phase 3 study in Crohn DiseaseNew to redhill-biopharma-limitedredhill-biopharma-limited · NCT03009396 · 54 enrolled · United States, Canada, Czechia and more
- Jan 9, 2019Phase 1 study in HealthyJohnson & Johnson · NCT03800550 · 16 enrolled · Belgium
- Nov 15, 2019phathom-pharmaceuticals-inc's first study: phase 3 study in Helicobacter Pylori InfectionNew to phathom-pharmaceuticals-incphathom-pharmaceuticals-inc · NCT04167670 · 1,046 enrolled · United States, Bulgaria, Czechia and more
- May 15, 2020Sihuan Pharmaceutical Holdings Group's first study: phase 1 study in Healthy Male VolunteersNew to Sihuan Pharmaceutical Holdings GroupSihuan Pharmaceutical Holdings Group · NCT04444011 · 32 enrolled
- Oct 28, 2021antios-therapeutics-inc's first study: phase 1 study in Drug Drug InteractionNew to antios-therapeutics-incantios-therapeutics-inc · NCT05137600 · 36 enrolled · Canada
- Apr 26, 2023Italfarmaco's first study: phase 1 study in Drug Drug InteractionNew to ItalfarmacoItalfarmaco · NCT05845567 · 20 enrolled · Portugal
- Jun 2, 2023shandong-luoxin-pharmaceutical-group-stock-co-ltd's first study: phase 1 study in HealthyNew to shandong-luoxin-pharmaceutical-group-stock-co-ltdshandong-luoxin-pharmaceutical-group-stock-co-ltd · NCT05915871 · 22 enrolled · China
- Jul 6, 2026Jiangsu HengRui Medicine's first study: phase 1 study in Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary DiseaseNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT07696091 · 40 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule
Studies
All 39 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07696091Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease · China | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Sep 2026 | 40 |
| NCT05915871Healthy · China | 1 | Completed | shandong-luoxin-pharmaceutical-group-stock-co-ltd | Apr 28, 2023 | 22 |
| NCT05845567Drug Drug Interaction · Portugal | 1 | Completed | Italfarmaco | May 8, 2022 | 20 |
| NCT05137600Drug Drug Interaction · Canada | 1 | Completed | antios-therapeutics-inc | Dec 23, 2021 | 36 |
| NCT04444011Healthy Male Volunteers | 1 | UNKNOWN | Sihuan Pharmaceutical Holdings Group | Sep 30, 2020 | 32 |
| NCT04167670Helicobacter Pylori Infection · United States, Bulgaria, Czechia and more | 3 | Completed | phathom-pharmaceuticals-inc | Mar 10, 2021 | 1,046 |
| NCT03800550Healthy · Belgium | 1 | Completed | Johnson & Johnson | Jun 4, 2019 | 16 |
| NCT03009396Crohn Disease · United States, Canada, Czechia and more | 3 | Completed | redhill-biopharma-limited | Nov 13, 2018 | 54 |
| NCT03011996Drug Interaction · Korea, Republic of | 1 | Completed | HK inno.N | Feb 2017 | 60 |
| NCT02343289Healthy · Belgium | 1 | Completed | Johnson & Johnson | Apr 2015 | 18 |
| NCT02286635Healthy Volunteers · United States | 1 | Completed | PTC Therapeutics | Dec 2014 | 58 |
| NCT02251769Healthy | 1 | Completed | Boehringer Ingelheim | Sep 2003 | 24 |
| NCT02052336Healthy · Korea, Republic of | 1 | Completed | HK inno.N | Jan 2014 | 24 |
| NCT01921647Healthy · Korea, Republic of | 1 | Completed | Yuhan | Nov 2013 | 95 |
| NCT00881738Healthy | 1 | Completed | Novartis | Jun 2002 | 32 |
| NCT00881179Healthy | 1 | Completed | Novartis | Jun 2002 | 24 |
| NCT00840411Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2002 | 66 |
| NCT00840216Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Aug 2002 | 22 |
| NCT00836706Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2002 | 24 |
| NCT00835692Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2002 | 60 |
| NCT00775372Healthy · India | – | Completed | Sun Pharmaceutical Industries | Oct 2005 | 40 |
| NCT00775255Healthy · India | – | Completed | Sun Pharmaceutical Industries | Sep 2005 | 40 |
| NCT00774696Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Dec 2002 | 24 |
| NCT00774644Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Jan 2003 | 33 |
| NCT00774189Healthy · India | 1 | Completed | Sun Pharmaceutical Industries | Aug 2003 | 32 |
| NCT00648960Healthy · Canada | 1 | Completed | Viatris | Jul 2003 | 64 |
| NCT00648830Healthy · Canada | 1 | Completed | Viatris | Jun 2004 | 32 |
| NCT00648128Healthy · Canada | 1 | Completed | Viatris | Mar 2003 | 44 |
| NCT00645086Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB). · United States, Canada, Puerto Rico | 3 | Completed | Abbott | Apr 2004 | 465 |
| NCT00644553Acute Bacterial Sinusitis (ABS) · United States, Canada, Greece and more | 3 | Completed | Abbott | Mar 2004 | 437 |
| NCT00643227Pneumonia · United States, Argentina, Canada and more | 3 | Completed | Pfizer | 504 | |
| NCT00602498Infections · United States | – | Completed | Hikma Pharmaceuticals | Mar 2003 | 28 |
| NCT00601315Infections · United States | – | Completed | Hikma Pharmaceuticals | May 2003 | 40 |
| NCT00002336HIV Infections · United States | – | Completed | Abbott | Nov 1994 | |
| NCT00002331HIV Infections · United States, Puerto Rico | – | Completed | Abbott | Mar 1995 | |
| NCT00002194HIV Infections · United States | 1 | Completed | Boehringer Ingelheim | 36 | |
| NCT00002140Mycobacterium avium-intracellulare Infection · United States | 3 | Completed | Pfizer | ||
| NCT00002101Mycobacterium avium-intracellulare Infection · United States | 3 | Completed | Pfizer | 450 | |
| NCT00000971Mycobacterium avium-intracellulare Infection · United States | 1 | Completed | Abbott | 24 |
How it is read
Names in the registry
- “Clarithromycin”, 23 entries
- “clarithromycin”, 2 entries
- “Clarithromycin ER 500 mg tablets”, 2 entries
- “Clarithromycin 500mg”, 2 entries
- “RSS0343 Tablet; Clarithromycin Tablets”, 1 entry
Conditions, from the studies’ own filings
- Mycobacterium avium-intracellulare Infection, 3 studies
- Infections, 2 studies
- HIV Infections, 2 studies
- Bronchiectasis, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.